Government News

India may have emerged as a key supplier of generic and affordable medicine  for the world market, its overwhelming dependence on China for a crucial raw material , known as Active Pharmaceutical Ingredient (API)to the extent of over 65 percent of the requirement, has emerged as a main worrying area.

DCGI (Drugs Controller General of India) extends validity of approval of Bioavailability and Bioequivalence Centre from one year to three years to facilitate ease of working.

In line with the vision of Shri Narendra Modi, Hon’ble Prime Minister of India to eradicate Leprosy from India, Shri J P Nadda, Union Minister of Health and Family Welfare reviewed the National Leprosy Eradication Programme and pursuant to that, Ministry of Health and Family Welfare has launched the biggest Leprosy Case Detection Campaign (LCDC) in the country on 5th September 2016 across 149 districts of 19 states/UTs.

The Union Minister for Chemicals & Fertilizers and Parliamentary Affairs Sh. Ananth Kumar has said that Promotion and Regulation should go hand in hand for medical devices sector to provide affordable health care to the poor. Speaking at the 9th Medical Technology Conference in New Delhi today he said that regulation is required in the medical devices sector to check profit and money making so as to facilitate providing adequate medical facilities to the poor.

The Indian Health ministry has taken different steps to ease the conductance of clinical trials in India by creating strong regulatory platform for ensuring safety, rights and well beings of the clinical research.

NPPA has revised ceiling price of 24 formulations and retail price of 31 formulations which includes from anticancer, antidiabetic, antiviral, antibacterial, antifungal etc portfolios.

[adsense:336x280:8701650588]

Foreign Direct Investment (FDI) in Brownfield pharma sector has been permitted upto 74% under automatic route; and FDI beyond 74% and upto 100% is allowed under Government approval route.

The Competition Commission of India (Commission) has found the Karnataka Chemists and Druggist Association (KCDA) and Lupin Ltd. (Lupin) to be in contravention of the provisions of the Competition Act, 2002 (the Act). In a case filed by M/s Maruti & Co., it was brought to the notice of the Commission that KCDA restraints pharmaceutical companies from appointing new stockists in the State of Karnataka unless a No Objection Certificate (NOC) is obtained from it.